Donald Foster, DO
Family Medicine · Elmira, NYNPI 1679960066
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 55.3% of the total. Reporting peaked in 2023 at $721 and has fallen 71.2% since, to $207 in 2025.
Across 79 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$927
- Indivior Inc.$193
- Gilead$168
- Alkermes, Inc.$79
- Johnson & Johnson$64
- Braeburn Inc.$39
- plus $205 from 9 others
What the payments were for
- Food & beverage$1,65299%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 46 | $927 |
| Indivior Inc. | 8 | $193 |
| Gilead | 5 | $168 |
| Alkermes, Inc. | 4 | $79 |
| Johnson & Johnson | 2 | $64 |
| Braeburn Inc. | 2 | $39 |
| Novo Nordisk | 2 | $35 |
| Pfizer | 2 | $29 |
| Corium, LLC | 2 | $27 |
| Lilly USA, LLC | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Organon | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$1,674 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 160 | $17,217 |
| OxycontinOxycodone Hcl | 12 | $8,270 |
| Pregabalin | 52 | $5,119 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 35 | $4,437 |
| BelbucaBuprenorphine Hcl | 14 | $4,314 |
| Buprenorphine Hcl | 93 | $3,516 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $591 |
| Oxycodone Hcl | 31 | $540 |
| Gabapentin | 57 | $536 |
| Alprazolam | 47 | $486 |
| Clonazepam | 38 | $481 |
| Bupropion XlBupropion Hcl | 24 | $477 |
| Methocarbamol | 14 | $461 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $401 |
| Duloxetine Hcl | 15 | $379 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Elmira
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.